Vyberte zemi nebo region

Nyní se nacházíte v části Czech Republic (Česky)
Domovská stránka / O nás / Investors / Newsroom / Board members and senior executives in Arjo have acquired synthetic share options in Arjo from Carl Bennet AB
❮ Novinky

Board members and senior executives in Arjo have acquired synthetic share options in Arjo from Carl Bennet AB

The Board of Directors in Arjo AB has today been informed by the company’s principal shareholder, Carl Bennet AB, that board members and senior executives in Arjo have acquired synthetic share options in Arjo issued by Carl Bennet AB.

“It is very gratifying that everyone that received the offer to acquire synthetic options have chosen to subscribe," says Carl Bennet, principal owner of Arjo. This commitment shows a high motivation for the company and its future development, "concludes Carl Bennet.

As stated in the prospectus for admission to trading of the shares in Arjo, Carl Bennet AB has offered all board members elected by the general meeting and all members of the Executive Management Team in Arjo to acquire synthetic share options in Arjo issued by Carl Bennet AB. Today, the Board of Directors in Arjo was informed by Carl Bennet AB that everyone who has received the offer has acquired options. According to the notification, 9,190,469 synthetic share options have been acquired in total, at a price deemed to correspond to the market value of the options. The total market value of the options at the time of the transaction has been calculated to SEK 19.3 million.

The synthetic share options are related to the Arjo Class B share with a maturity of four years and may be exercised during the period 1 October–31 December 2021. The exercise price per option is SEK 29,60, which corresponds to 122 per cent of the volume-weighted average price paid for the Arjo Class B share on Nasdaq Stockholm during the period 12–18 December 2017. When exercising the option, the option holder will receive a cash payment from Carl Bennet AB corresponding to the number of underlying Class B shares each option represents multiplied by the market value of the share reduced by the exercise price. The option holder will not receive any cash payment if the market value is less than the exercise price.

Arjo has not been involved in the offer that has been provided by, and solely on the initiative of, Carl Bennet AB to the board members and the Executive Management Team in Arjo.


For further information, please contact:

Kornelia Rasmussen
Executive Vice President
Marketing Communication and Public Relations
Tel: +46 (0)10 335 48 10
E-mail: kornelia.rasmussen@arjo.com
 


About Arjo 

At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has over 5,900 employees worldwide and customers in over 60 countries. In 2016 the Arjo sales amounted to about SEK 8 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.com  

Release
Potvrzuji, že jsem se seznámil s definicí odborníka ve smyslu zákona č. 40/1995 Sb. a že jsem tímto odborníkem.

Kliknutím na tlačítko ANO chci pokračovat na tyto webové stránky a výslovně potvrzuji následující:

  • Jsem odborníkem, tedy osobou oprávněnou předepisovat nebo vydávat zdravotnické prostředky nebo diagnostické zdravotnické prostředky in vitro, případně zaměstnancem poskytovatele zdravotnických služeb.
  • Je mi známa definice odborníka, případně vymezení zaměstnance poskytovatele zdravotnických služeb ve smyslu zákona č. 40/1995 Sb.
  • Beru na vědomí, že informace obsažené na těchto webových stránkách nejsou určeny pro laickou veřejnost, ale pouze pro odborníky a zaměstnance poskytovatelů zdravotnických služeb. Dále potvrzuji, že jsou mi známa rizika spojená s návštěvou těchto webových stránek jinou osobou než odborníkem nebo zaměstnancem poskytovatele zdravotnických služeb (např. neporozumění správnému fungování inzerovaných zdravotnických prostředků, nesprávný výběr zdravotnického prostředku nebo nesprávné učinění diagnózy).